PMID- 24714697
OWN - NLM
STAT- MEDLINE
DCOM- 20141203
LR  - 20211021
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 9
IP  - 4
DP  - 2014
TI  - MAML2 rearrangement in primary pulmonary mucoepidermoid carcinoma and the 
      correlation with FLT1 expression.
PG  - e94399
LID - 10.1371/journal.pone.0094399 [doi]
LID - e94399
AB  - INTRODUCTION: Primary pulmonary mucoepidermoid carcinoma (PMEC) is an uncommon 
      neoplasm with remarkable resemblance to mucoepidermoid carcinoma of the salivary 
      glands. The latter has been shown to harbor t(11,19) resulting in MECT1-MAML2 
      fusion, which may be of diagnostic and prognostic values. However, the importance 
      of such feature in PMEC has not been well studied. METHODS: We detected MAML2 
      rearrangement using fluorescence in situ hybridization (FISH) in tissue samples 
      from 42 cases of PMEC and 40 of adenosquamous carcinoma (ASC), and the expression 
      of potential downstream targets of MECT1-MAML2, including HES1, FLT1 and NR4A2 
      with immunohistochemistry (IHC). The findings were then examined regarding the 
      clinicopathological parameters and patient outcomes. RESULTS: FISH analysis 
      revealed MAML2 rearrangement in 50% of the PMEC cases, and such property was 
      prominent in considerable younger patients (33 versus 60 years; p = 0.001) and 
      restricted to cases of low and intermediate grades. IHC analysis showed that FLT1 
      and HES1 were expressed at lower level in MAML2 rearranged group than MAML2 
      non-rearranged group (p<0.001 and p = 0.023, respectively). Survival analysis 
      showed significant correlation between MAML2 rearrangement and overall survival 
      (p = 0.023) or disease-free survival (p = 0.027) as well as correlation between 
      FLT1 and overall survival (p = 0.009). CONCLUSIONS: MAML2 rearrangement appears 
      frequent in PMEC and specific with this tumor. Both the presence of MAML2 
      rearrangement and absence of FLT1 tend to confer a favorable clinical outcome. 
      These findings suggest that molecular detection of MAML2 rearrangement combined 
      with FLT1 may be of important clinical value for PMEC.
FAU - Zhu, Fen
AU  - Zhu F
AD  - Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
FAU - Wang, Weige
AU  - Wang W
AD  - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 
      China; Department of Oncology, Shanghai Medical College, Fudan University, 
      Shanghai, China.
FAU - Hou, Yingyong
AU  - Hou Y
AD  - Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Shi, Jindong
AU  - Shi J
AD  - The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, China.
FAU - Liu, Zilong
AU  - Liu Z
AD  - Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
FAU - He, Deming
AU  - He D
AD  - Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Bai, Chunxue
AU  - Bai C
AD  - Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
FAU - Li, Shanqun
AU  - Li S
AD  - Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
FAU - Jiang, Liyan
AU  - Jiang L
AD  - Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiaotong 
      University, Shanghai, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140408
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (MAML2 protein, human)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (Trans-Activators)
RN  - 0 (Transcription Factors)
RN  - EC 2.7.10.1 (FLT1 protein, human)
RN  - EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-1)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Carcinoma, Mucoepidermoid/*genetics/mortality/pathology
MH  - DNA-Binding Proteins/*genetics
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Staging
MH  - Nuclear Proteins/*genetics
MH  - Oncogene Proteins, Fusion/*genetics
MH  - Prognosis
MH  - Salivary Gland Neoplasms/*genetics/mortality/pathology
MH  - Trans-Activators
MH  - Transcription Factors/*genetics
MH  - Translocation, Genetic
MH  - Vascular Endothelial Growth Factor Receptor-1/*genetics
MH  - Young Adult
PMC - PMC3979848
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2014/04/10 06:00
MHDA- 2014/12/15 06:00
PMCR- 2014/04/08
CRDT- 2014/04/10 06:00
PHST- 2014/01/23 00:00 [received]
PHST- 2014/03/13 00:00 [accepted]
PHST- 2014/04/10 06:00 [entrez]
PHST- 2014/04/10 06:00 [pubmed]
PHST- 2014/12/15 06:00 [medline]
PHST- 2014/04/08 00:00 [pmc-release]
AID - PONE-D-14-02260 [pii]
AID - 10.1371/journal.pone.0094399 [doi]
PST - epublish
SO  - PLoS One. 2014 Apr 8;9(4):e94399. doi: 10.1371/journal.pone.0094399. eCollection 
      2014.